Background: Tranexamic acid (TXA) reduces perioperative blood loss in total hip arthroplasty (THA).
Methods: In our randomized control trial, 139 patients were enrolled and received 2 g of either topical or intravenous (IV) TXA. Preoperative and postoperative protocols were standardized.
Results: Calculated blood and Hgb loss were lower in the IV group (1195.0 ± 485.9 mL, 1442.7 ± 562.7 mL; P = .006), (160.3 [g] ± 63.8, 188.4 [g] ± 68.5; P = .014). There was a trend toward significance in transfusion reduction (11% [IV] vs 18% [topical]; P = .3). Both groups effectively reduced the transfusion rate. There was significant financial incentive for the use of TXA in THA with a savings of $314 per patient.
Conclusions: IV and topical TXA are effective tools to reduce blood loss and transfusion costs in THA, and we recommend the IV form for ease of use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.arth.2015.11.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The efficacy and safety of topical combined with intravenous administration of tranexamic acid in spine surgery: a systematic review and meta-analysis.
BMC Musculoskelet Disord
December 2024
Department of Orthopedics, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, Zhejiang, 317000, China.
Background: There is controversy regarding the efficacy of intravenous combined topical tranexamic acid. We conducted this study to systematically assess the effectiveness of intravenous combined topical tranexamic acid (combined TXA) in spinal surgery to guide clinical practice.
Methods: The review process was conducted according to the PRISMA guidelines.
Objective: To evaluate the clinical benefit and adverse events following outpatient intravenous (IV) ketamine-lidocaine (KL) infusions for palliation of cancer pain in dogs and cats.
Methods: Medical records from 15 years (2008 to 2023) were searched and data reviewed retrospectively. Animals were prescribed ketamine (0.
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy.
Cancer Chemother Pharmacol
December 2024
Department of Oncology, Tangdu Hospital, The Air Force Medical University, No.569 Xinsi Road, Xi'an, Shaanxi Province, 710038, China.
Objective: To compare the pharmacokinetics and adverse effects of cisplatin administered via intravenous infusion for systemic chemotherapy (SC) versus injection into the perfusate during hyperthermic intrathoracic chemotherapy (HITHOC) or hyperthermic intraperitoneal chemotherapy (HIPEC).
Methods: Total 60 patients who received SC, HITHOC, or HIPEC in the Department of Oncology, Tangdu Hospital, were enrolled into this study. After administering same dose of cisplatin (40 mg) via either intravenous infusion (SC group) or injection into the perfusate during the HITHOC or HIPEC procedure, concentration of cisplatin in the plasma as well as in the hyperthermic perfusate at various time points was quantified by HPLC analysis.
Enhancing transdermal delivery of chrysomycin A for the treatment of cutaneous melanoma and MRSA infections using Skin-Penetrating Peptide-Functionalized deformable liposomes.
Int J Pharm
December 2024
Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals & College of Pharmaceutical Science, Zhejiang University of Technology, 310014 Hangzhou, China; Zhejiang Key Laboratory of Green, Low-carbon and Efficient Development of Marine Fishery Resources, Hangzhou 310014, China. Electronic address:
Article Synopsis
- Transdermal drug delivery using SPACE-modified liposomal chrysomycin A (CA@SPACE-LP) shows promise for treating skin diseases like melanoma and MRSA infections.
- In vitro studies reveal that CA@SPACE-LP significantly enhances drug penetration into skin layers, achieving a threefold increase in intradermal drug concentration compared to free chrysomycin A.
- In vivo results indicate that CA@SPACE-LP effectively suppresses melanoma tumor growth by about 60% and outperforms conventional treatments for MRSA, suggesting its potential for combined cancer and infection therapy.
Development and evaluation of Amikacin-loaded carbopol hydrogel for topical treatment of Mycobacterium marinum skin infections.
Lett Appl Microbiol
December 2024
Amrita School for Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi-682041, India.
Mycobacterium marinum is a slow growing Non-Tuberculosis Mycobacteria (NTM) known to cause skin and subcutaneous tissue infections known as "fish tank granuloma" in humans. Treatment of M. marinum skin infections can last for several months or even years.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!